El-Sheikh Azza A K, van den Heuvel Jeroen J M W, Koenderink Jan B, Russel Frans G M
Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Department of Pharmacology and Toxicology 149, P O Box 9101, 6500 HB Nijmegen, The Netherlands.
J Pharmacol Exp Ther. 2007 Jan;320(1):229-35. doi: 10.1124/jpet.106.110379. Epub 2006 Sep 27.
Methotrexate (MTX) has been used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of inflammatory diseases as well as malignancies. Especially at high MTX dosages, severe adverse effects with this combination may occur, usually resulting from an impaired renal elimination. It has been shown that the mechanism of this interaction cannot be fully attributed to inhibition of basolateral MTX uptake in renal proximal tubules. Here, we studied the effect of various NSAIDs on MTX transport in membrane vesicles isolated from cells overexpressing the proximal tubular apical efflux transporters human multidrug resistance protein (MRP) 2/ABCC2 and MRP4/ABCC4. MTX was transported by MRP2 and MRP4 with Km values of 480 +/- 90 and 220 +/- 70 microM, respectively. The inhibitory potency of the NSAIDs was generally higher against MRP4- than MRP2-mediated MTX transport, with therapeutically relevant IC50 values, ranging from approximately 2 microM to 1.8 mM. Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model. In some cases, more complex interaction patterns were observed. Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and ketoprofen followed a two-site competition model. Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration. Our data suggest that the inhibition by NSAIDs of renal MTX efflux via MRP2 and MRP4 is a potential new site and mechanism contributing to the overall interaction between these drugs.
甲氨蝶呤(MTX)已与非甾体抗炎药(NSAIDs)联合用于治疗炎症性疾病和恶性肿瘤。特别是在高剂量MTX时,这种联合用药可能会产生严重的不良反应,通常是由于肾脏排泄受损所致。研究表明,这种相互作用的机制不能完全归因于肾近端小管基底外侧MTX摄取的抑制。在此,我们研究了各种NSAIDs对从过表达近端小管顶端外排转运体人多药耐药蛋白(MRP)2/ABCC2和MRP4/ABCC4的细胞中分离出的膜囊泡中MTX转运的影响。MTX由MRP2和MRP4转运,Km值分别为480±90和220±70μM。NSAIDs对MRP4介导的MTX转运的抑制效力通常高于对MRP2介导的MTX转运的抑制效力,其治疗相关IC50值范围约为2μM至1.8 mM。水杨酸、吡罗昔康、布洛芬、萘普生、舒林酸、托美丁和依托度酸根据单点竞争模型抑制MRP2和MRP4介导的MTX转运。在某些情况下,观察到更复杂的相互作用模式。双氯芬酸对MRP4的抑制以及吲哚美辛和酮洛芬对MRP2的抑制遵循两点竞争模型。保泰松在低浓度时刺激MRP2和塞来昔布刺激MRP4转运,而在高浓度时抑制这两种转运体。我们的数据表明,NSAIDs通过MRP2和MRP4抑制肾脏MTX外排是这些药物之间总体相互作用的一个潜在新位点和机制。